Loading…
Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs
•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infectio...
Saved in:
Published in: | Vaccine 2023-10, Vol.41 (42), p.6150-6155 |
---|---|
Main Authors: | , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53 |
---|---|
cites | cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53 |
container_end_page | 6155 |
container_issue | 42 |
container_start_page | 6150 |
container_title | Vaccine |
container_volume | 41 |
creator | Salat, Jiri Hunady, Milan Svoboda, Pavel Strelcova, Lucie Strakova, Petra Fortova, Andrea Palus, Martin Ruzek, Daniel |
description | •An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection.
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections. |
doi_str_mv | 10.1016/j.vaccine.2023.09.019 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2865783426</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X23010897</els_id><sourcerecordid>2865783426</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</originalsourceid><addsrcrecordid>eNqFkc2LUzEUxYMoWMf5E4SAGzfvefP1PlYiw-gIA24U3IUkL6m3tklN0kL_-0lpV7OZ1V3c3zmXew4hHxj0DNjwedMfjXMYfc-Bix7mHtj8iqzYNIqOKza9Jivgg-wkgz9vybtSNgCgBJtXxN-HgM64EzVxobjbHWJa-4gO64mmQA09-uozRpNP9HqGusbiYqqnZm0wlkorun-dTbktfXR-_9dssWKhGOmS1uU9eRPMtvjb67whv7_d_7p76B5_fv9x9_WxcxJE7UYWZFAOPBd8YcrZYAy3c7BWKaucCT4oaUZuJZtcCKahYQqgghWcT1aJG_Lp4rvP6f_Bl6p3WJzfbk306VC0AAlSSTXCiyifBjVOQvKhoR-foZt0yLE90qgR-DgOUjZKXSiXUynZB73PuGuxaQb63JPe6GuA-tyThlm3npruy0XnWzBH9FkXh-cQF8zeVb0kfMHhCZL3n-Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2870277644</pqid></control><display><type>article</type><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><source>Elsevier</source><creator>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</creator><creatorcontrib>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</creatorcontrib><description>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection.
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2023.09.019</identifier><language>eng</language><publisher>Kidlington: Elsevier Ltd</publisher><subject>Animals ; Antibodies ; Antigens ; Apathy ; Arachnids ; Bacterial infections ; Dogs ; Effectiveness ; Encephalitis ; Females ; Immunization ; Immunogenicity ; Infections ; Males ; Tick-borne encephalitis ; Tick-borne encephalitis virus ; vaccination ; Vaccine ; Vaccines ; viral antigens ; Viremia ; Viruses</subject><ispartof>Vaccine, 2023-10, Vol.41 (42), p.6150-6155</ispartof><rights>2023 Elsevier Ltd</rights><rights>2023. Elsevier Ltd</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</citedby><cites>FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</cites><orcidid>0000-0003-4655-2380</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids></links><search><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Hunady, Milan</creatorcontrib><creatorcontrib>Svoboda, Pavel</creatorcontrib><creatorcontrib>Strelcova, Lucie</creatorcontrib><creatorcontrib>Strakova, Petra</creatorcontrib><creatorcontrib>Fortova, Andrea</creatorcontrib><creatorcontrib>Palus, Martin</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><title>Vaccine</title><description>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection.
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</description><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Apathy</subject><subject>Arachnids</subject><subject>Bacterial infections</subject><subject>Dogs</subject><subject>Effectiveness</subject><subject>Encephalitis</subject><subject>Females</subject><subject>Immunization</subject><subject>Immunogenicity</subject><subject>Infections</subject><subject>Males</subject><subject>Tick-borne encephalitis</subject><subject>Tick-borne encephalitis virus</subject><subject>vaccination</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>viral antigens</subject><subject>Viremia</subject><subject>Viruses</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkc2LUzEUxYMoWMf5E4SAGzfvefP1PlYiw-gIA24U3IUkL6m3tklN0kL_-0lpV7OZ1V3c3zmXew4hHxj0DNjwedMfjXMYfc-Bix7mHtj8iqzYNIqOKza9Jivgg-wkgz9vybtSNgCgBJtXxN-HgM64EzVxobjbHWJa-4gO64mmQA09-uozRpNP9HqGusbiYqqnZm0wlkorun-dTbktfXR-_9dssWKhGOmS1uU9eRPMtvjb67whv7_d_7p76B5_fv9x9_WxcxJE7UYWZFAOPBd8YcrZYAy3c7BWKaucCT4oaUZuJZtcCKahYQqgghWcT1aJG_Lp4rvP6f_Bl6p3WJzfbk306VC0AAlSSTXCiyifBjVOQvKhoR-foZt0yLE90qgR-DgOUjZKXSiXUynZB73PuGuxaQb63JPe6GuA-tyThlm3npruy0XnWzBH9FkXh-cQF8zeVb0kfMHhCZL3n-Y</recordid><startdate>20231006</startdate><enddate>20231006</enddate><creator>Salat, Jiri</creator><creator>Hunady, Milan</creator><creator>Svoboda, Pavel</creator><creator>Strelcova, Lucie</creator><creator>Strakova, Petra</creator><creator>Fortova, Andrea</creator><creator>Palus, Martin</creator><creator>Ruzek, Daniel</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>7S9</scope><scope>L.6</scope><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid></search><sort><creationdate>20231006</creationdate><title>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</title><author>Salat, Jiri ; Hunady, Milan ; Svoboda, Pavel ; Strelcova, Lucie ; Strakova, Petra ; Fortova, Andrea ; Palus, Martin ; Ruzek, Daniel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Apathy</topic><topic>Arachnids</topic><topic>Bacterial infections</topic><topic>Dogs</topic><topic>Effectiveness</topic><topic>Encephalitis</topic><topic>Females</topic><topic>Immunization</topic><topic>Immunogenicity</topic><topic>Infections</topic><topic>Males</topic><topic>Tick-borne encephalitis</topic><topic>Tick-borne encephalitis virus</topic><topic>vaccination</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>viral antigens</topic><topic>Viremia</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salat, Jiri</creatorcontrib><creatorcontrib>Hunady, Milan</creatorcontrib><creatorcontrib>Svoboda, Pavel</creatorcontrib><creatorcontrib>Strelcova, Lucie</creatorcontrib><creatorcontrib>Strakova, Petra</creatorcontrib><creatorcontrib>Fortova, Andrea</creatorcontrib><creatorcontrib>Palus, Martin</creatorcontrib><creatorcontrib>Ruzek, Daniel</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>ProQuest Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Healthcare Administration Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Research Library (ProQuest Database)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>AGRICOLA</collection><collection>AGRICOLA - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salat, Jiri</au><au>Hunady, Milan</au><au>Svoboda, Pavel</au><au>Strelcova, Lucie</au><au>Strakova, Petra</au><au>Fortova, Andrea</au><au>Palus, Martin</au><au>Ruzek, Daniel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs</atitle><jtitle>Vaccine</jtitle><date>2023-10-06</date><risdate>2023</risdate><volume>41</volume><issue>42</issue><spage>6150</spage><epage>6155</epage><pages>6150-6155</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>•An inactivated whole-virion TBEV vaccine candidate for dogs was developed.•The vaccine candidate was tested in mice and in dogs.•The vaccine was well tolerated and elicited production of neutralizing anti-TBEV antibodies.•Vaccination of mice provided complete protection against lethal TBEV infection.•Vaccination of dogs prevented the development of viremia after challenge infection.
Tick-borne encephalitis (TBE) is a severe neuroinfection of humans. Dogs are also commonly infected with tick-borne encephalitis virus (TBEV). These infections are usually asymptomatic, but sometimes show clinical signs similar to those seen in humans and can be fatal. To date, there is no TBEV vaccine available for use in dogs. To address this need, a TBEV vaccine candidate for dogs based on inactivated whole virus antigen was developed. The safety, immunogenicity, and efficacy of the vaccine candidate were tested in mice as the preclinical model and in dogs as the target organism. The vaccine was well tolerated in both species and elicited the production of specific anti-TBEV antibodies with virus neutralising activity. Vaccination of mice provided complete protection against the development of fatal TBE. Immunisation of dogs prevented the development of viremia after challenge infection. Therefore, the developed vaccine candidate is promising to protect dogs from severe TBEV infections.</abstract><cop>Kidlington</cop><pub>Elsevier Ltd</pub><doi>10.1016/j.vaccine.2023.09.019</doi><tpages>6</tpages><orcidid>https://orcid.org/0000-0003-4655-2380</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0264-410X |
ispartof | Vaccine, 2023-10, Vol.41 (42), p.6150-6155 |
issn | 0264-410X 1873-2518 |
language | eng |
recordid | cdi_proquest_miscellaneous_2865783426 |
source | Elsevier |
subjects | Animals Antibodies Antigens Apathy Arachnids Bacterial infections Dogs Effectiveness Encephalitis Females Immunization Immunogenicity Infections Males Tick-borne encephalitis Tick-borne encephalitis virus vaccination Vaccine Vaccines viral antigens Viremia Viruses |
title | Efficacy and immunogenicity of a veterinary vaccine candidate against tick-borne encephalitis in dogs |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T10%3A41%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20immunogenicity%20of%20a%20veterinary%20vaccine%20candidate%20against%20tick-borne%20encephalitis%20in%20dogs&rft.jtitle=Vaccine&rft.au=Salat,%20Jiri&rft.date=2023-10-06&rft.volume=41&rft.issue=42&rft.spage=6150&rft.epage=6155&rft.pages=6150-6155&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2023.09.019&rft_dat=%3Cproquest_cross%3E2865783426%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c403t-71f4f5c0e232d15cbfaa2b9fbb55b5cafef54a72b418cffa5c0f8f05fb3228b53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2870277644&rft_id=info:pmid/&rfr_iscdi=true |